# ACXP catalysts: Acurx Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/acxp/catalysts

> Acurx Pharmaceuticals, Inc. (ACXP) has 2 upcoming catalysts. The next is the ibezapolstat topline data readout, Sep to Dec 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Acurx Pharmaceuticals, Inc. |
| Ticker | ACXP (Nasdaq) |
| SEC CIK | 1736243 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/acxp |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 25, 2024 | [CRS3123 trial start](https://sec-api.dev/pdufa/crs3123) | ACXP |  | completed | "On September 25, 2024, the Company announced it had completed a Phase 2 clinical trial but there are no indications publicly that Crestone has commenced Phase 3 trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1736243/000110465926027052/acxp-20251231x10k.htm)) |
| November 13, 2024 | [Acurx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/acxp/catalysts) | ACXP |  | completed | "Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/tm2428175d1_ex99-1.htm)) |
| March 18, 2025 | [Acurx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/acxp/catalysts) | ACXP |  | completed | "Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736243/000110465925024731/tm259528d1_ex99-1.htm)) |
| May 13, 2025 | [Acurx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/acxp/catalysts) | ACXP |  | completed | "Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736243/000110465925047566/tm2514876d1_ex99-1.htm)) |
| Sep to Dec 2027 | [Ibezapolstat topline data readout](https://sec-api.dev/pdufa/ibezapolstat) | ACXP | Clostridium Difficile Infection Recurrence | scheduled | "NCT07513285 (ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Acurx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07513285)) |
| September 2027 | [Ibezapolstat primary completion](https://sec-api.dev/pdufa/ibezapolstat) | ACXP | Clostridium Difficile Infection Recurrence | scheduled | "NCT07513285 (ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Acurx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07513285)) |

## Drugs

- [CRS3123](https://sec-api.dev/pdufa/crs3123): 
- [Ibezapolstat](https://sec-api.dev/pdufa/ibezapolstat): Clostridium Difficile Infection Recurrence

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/acxp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACXP catalysts: Acurx Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/acxp/catalysts

```bibtex
@misc{secapidev_companies_acxp_catalysts_20261116,
  title        = {ACXP catalysts: Acurx Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/acxp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_acxp_catalysts_20261116","title":"ACXP catalysts: Acurx Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/acxp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
